NASDAQ:KYMR Kymera Therapeutics (KYMR) Stock Price, News & Analysis $105.98 -3.87 (-3.52%) Closing price 10/6/2026 04:00 PM EasternExtended Trading$105.75 -0.23 (-0.22%) As of 08:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Kymera Therapeutics Stock (NASDAQ:KYMR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kymera Therapeutics alerts:Sign Up Key Stats Today's Range$101.75▼$111.0450-Day Range$100.31▼$127.3152-Week Range$55.26▼$130.05Volume960,663 shsAverage Volume800,295 shsMarket Capitalization$8.81 billionP/E RatioN/ADividend YieldN/APrice Target$134.46Consensus RatingModerate Buy Company Overview Kymera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing medicines that selectively remove disease-causing proteins from cells. The company uses its targeted protein degradation platform, including molecular glue degraders, to address proteins that may be difficult to inhibit with conventional small-molecule drugs. Kymera’s research and development activities center on immune-inflammatory diseases and cancer. Its pipeline has included investigational degraders designed to target proteins such as interleukin-1 receptor-associated kinase 4 (IRAK4) and signal transducer and activator of transcription 6 (STAT6), with the goal of treating conditions involving abnormal immune signaling. The company does not have a marketed product and remains focused on advancing its candidates through clinical development. Founded in 2016 and headquartered in Watertown, Massachusetts, Kymera conducts research and clinical development primarily in the United States while working with international collaborators and partners. The company was co-founded by Nello Mainolfi, Ph.D., who has served as its president and chief executive officer and remains associated with the company’s scientific and corporate leadership.AI Generated. May Contain Errors. Read More Kymera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreKYMR MarketRank™: Kymera Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 581st out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingKymera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 22 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialKymera Therapeutics has a consensus price target of $134.46, representing about 26.9% upside from its current price of $105.98.Amount of Analyst CoverageKymera Therapeutics has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kymera Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kymera Therapeutics are expected to decrease in the coming year, from ($3.83) to ($5.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kymera Therapeutics is -32.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kymera Therapeutics is -32.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKymera Therapeutics has a P/B Ratio of 5.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kymera Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.07% of the float of Kymera Therapeutics has been sold short.Short Interest Ratio / Days to CoverKymera Therapeutics has a short interest ratio ("days to cover") of 16.13, which indicates bearish sentiment.Change versus previous monthShort interest in Kymera Therapeutics has recently increased by 1.54%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKymera Therapeutics does not currently pay a dividend.Dividend GrowthKymera Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.33 News SentimentKymera Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Kymera Therapeutics this week, compared to 7 articles on an average week.Search Interest12 people have searched for KYMR on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Kymera Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Kymera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,108,324.00 in company stock.Percentage Held by Insiders15.98% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsKymera Therapeutics has minimal institutional ownership at this time.Read more about Kymera Therapeutics' insider trading history. Receive KYMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KYMR Stock News HeadlinesKymera Therapeutics (NASDAQ:KYMR) Stock: Insider Nello Mainolfi Sells 30,000 SharesOctober 3, 2026 | americanbankingnews.comKymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares of StockOctober 2, 2026 | insidertrades.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 7 at 1:00 AM | Stansberry Research (Ad)Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law FirmSeptember 30, 2026 | prnewswire.comKymera Therapeutics en foro Stifel: ruta acelerada para su fármaco líderSeptember 24, 2026 | mx.investing.comKymera Therapeutics al forum Stifel: percorso accelerato per il farmaco principaleSeptember 24, 2026 | it.investing.comPiper Sandler维持Kymera Therapeutics股票"增持"评级，目标价$140September 23, 2026 | cn.investing.comPiper Sandler conferma il rating su Kymera Therapeutics a $140September 23, 2026 | it.investing.comSee More Headlines KYMR Stock Analysis - Frequently Asked Questions How have KYMR shares performed this year? Kymera Therapeutics' stock was trading at $77.81 at the start of the year. Since then, KYMR stock has increased by 36.2% and is now trading at $105.98. How were Kymera Therapeutics' earnings last quarter? Kymera Therapeutics, Inc. (NASDAQ:KYMR) issued its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.09. The business's quarterly revenue was up 465.2% on a year-over-year basis. Read the conference call transcript. When did Kymera Therapeutics IPO? Kymera Therapeutics (KYMR) raised $148 million in an IPO on Friday, August 21st 2020. The company issued 8,684,800 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO. How do I buy shares of Kymera Therapeutics? Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kymera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kymera Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and First Solar (FSLR). Company Calendar Last Earnings8/05/2026Today10/06/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 KYMR's financial health is in the Green zone, according to TradeSmith. KYMR has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KYMR CIK1815442 Webwww.kymeratx.com Phone(857) 285-5314FaxN/AEmployees273Year Founded2017Price Target and Rating Average Price Target for Kymera Therapeutics$134.46 High Price Target$180.00 Low Price Target$97.00 Potential Upside/Downside+26.9%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)($3.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$311.35 million Net Margins-285.33% Pretax Margin-285.33% Return on Equity-21.22% Return on Assets-19.21% Debt Debt-to-Equity RatioN/A Current Ratio10.34 Quick Ratio10.34 Sales & Book Value Annual Sales$39.21 million Price / Sales224.74 Cash FlowN/A Price / Cash FlowN/A Book Value$19.42 per share Price / Book5.46Miscellaneous Outstanding Shares83,150,000Free Float69,863,000Market Cap$8.81 billion OptionableOptionable Beta1.98 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:KYMR) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe Executive Order That Quietly Changed What Your Dollar MeansOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
